Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Michael S. Gordon, Kim Allyson Margolin, Moshe Talpaz et al. · Journal of Clinical Oncology · 2001
PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: Cohorts of patients with metastatic cancer having failed prior therapy entered a phase I trial of rhuMAb VEGF administered by a 90-minute intravenous infusion at doses from 0.1 to 10.0 mg/kg on days 0, 28, 35, and 42. Patients underwent pharmacokinetic sampling on day 0 and had serum samples obtained during the subsequent 28 days. Response assessment was carried out on days 49 and 72. RESULTS: Twenty-five patients with a median Eastern Cooperative Oncology Group performance status of 0 were accrued. There were no grade III or IV adverse events definitely related to the antibody. There were three episodes of tumor-related bleeding. Infusions of rhuMAb VEGF were well tolerated without significant toxicity. Grades I and II adverse events possibly or probably related to study drug included asthenia, headache, and nausea. Pharmacokinetics revealed a linear profile with a half-life of 21 days. There were no objective responses, though 12 patients experienced stable disease over the duration of the study. CONCLUSION: rhuMAb VEGF was safely administered without dose-limiting toxicity at doses ranging up to 10 mg/kg. Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies. Subsequent trials will explore rhuMAb VEGF alone and in combination chemotherapy.
Cited by 913 works. doi:10.1200/jco.2001.19.3.843
Authors
- Michael S. Gordon
- Kim Allyson Margolin
- Moshe Talpaz
- George W. Sledge
- Eric B. Holmgren
- Robert S. Benjamin
- Susan Stalter
- Steven Shak
- Daniel C. Adelman
References
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- The Biology of Vascular Endothelial Growth Factor
- Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
- Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
- Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb
- The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies
- Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogenesis
- Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
- Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★